Related Experiment Videos
Crack-growth properties of various elastomers with potential application in small joint prostheses
D T Hutchinson1, K M Savory, K N Bachus
1Department of Orthopaedics, University of Utah School of Medicine, Salt Lake City 84132, USA.
Journal of Biomedical Materials Research
|October 23, 1997
Summary
New elastomeric materials, ChronoFlex, Medicaflex, and Santoprene, show significantly lower crack-growth rates than Silastic. These materials offer potential for longer-lasting small joint spacers for the metacarpophalangeal joint.
Area of Science:
- Biomaterials science
- Orthopedic implant materials
- Polymer engineering
Background:
- Silastic small joint spacers for metacarpophalangeal joints have a high failure rate (2-26%).
- Failure is speculated to result from flaw propagation on the material surface, introduced during manufacturing, handling, or use.
- A need exists for improved elastomeric materials with enhanced durability.
Purpose of the Study:
- To compare the crack-growth properties of novel elastomeric materials with Silastic.
- To identify a self-hinging joint spacer material with increased functional life.
- To evaluate polyurethanes (ChronoFlex, Medicaflex) and a thermoplastic elastomer (Santoprene) against Silastic.
Main Methods:
- Materials were sterilized using ethylene oxide or gamma irradiation.
- Crack-growth properties were assessed using an ASTM standard flexing machine.
- Testing was conducted under high humidity and body temperature, both before and after artificial aging.
Main Results:
- ChronoFlex, Medicaflex, and Santoprene exhibited significantly lower crack-growth rates compared to Silastic (p < 0.001).
- All tested materials demonstrated improved crack resistance over Silastic under simulated physiological conditions.
Conclusions:
- Polyurethanes (ChronoFlex, Medicaflex) and Santoprene show promise as superior alternatives to Silastic for small joint spacers.
- These materials may offer enhanced longevity and reduced failure rates in metacarpophalangeal joint implants.
- Further clinical evaluation is warranted to confirm the long-term efficacy of these novel biomaterials.